Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August J. Troendle sold 36,196 shares of the firm's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the sale, the chief executive officer directly owned 925,799 shares in the company, valued at approximately $440,587,744.10. The trade was a 3.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Medpace Stock Up 1.0%
Shares of NASDAQ MEDP traded up $4.64 during midday trading on Friday, hitting $486.98. The stock had a trading volume of 233,792 shares, compared to its average volume of 316,283. The company has a market capitalization of $13.68 billion, a price-to-earnings ratio of 36.21, a PEG ratio of 3.06 and a beta of 1.44. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30. The company has a fifty day moving average price of $412.68 and a 200 day moving average price of $344.19.
Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company's revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.
Institutional Investors Weigh In On Medpace
Hedge funds and other institutional investors have recently bought and sold shares of the business. Sone Capital Management LLC bought a new stake in shares of Medpace in the 4th quarter valued at approximately $1,318,000. GAMMA Investing LLC increased its stake in Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company's stock valued at $94,000 after purchasing an additional 83 shares during the last quarter. Fundsmith LLP bought a new stake in Medpace during the fourth quarter valued at $42,372,000. Hsbc Holdings PLC increased its stake in Medpace by 157.5% during the first quarter. Hsbc Holdings PLC now owns 4,364 shares of the company's stock valued at $1,296,000 after purchasing an additional 2,669 shares during the last quarter. Finally, Park Avenue Securities LLC increased its stake in Medpace by 1.8% during the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after purchasing an additional 48 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities analysts have recently weighed in on MEDP shares. Cowen lowered Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Mizuho raised their target price on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Robert W. Baird raised their target price on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Truist Financial raised their target price on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Finally, William Blair reiterated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, Medpace presently has an average rating of "Reduce" and a consensus target price of $412.73.
View Our Latest Research Report on Medpace
About Medpace
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
See Also
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
